Below is our recent interview with Jonathan M.N. Rigby, CEO of Immune Regulation:
Q: For those who have never heard of it, how would you describe Immune Regulation?
A: Immune Regulation is a clinical stage biotech company, pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases.
Existing therapies are designed to suppress the immune system and require chronic dosing to treat the inflammation, frequently causing severe side effects.
Our first-in-class drug immune-resetting therapies have demonstrated unique efficacy and safety in preclinical and human studies without suppressing the immune system. These therapies exhibit a short pharmacokinetic activity but reset the immune system from a pro-inflammatory to a regulatory state to induce long-term disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies.
Q: You’ve recently raised your new funding round; can you tell us something more?
A: Today, Immune Regulation announced a ~$53 Million dollar financing led by Morningside Ventures with participation from existing investors 24Haymarket. Needless to say, we are very happy about having Morningside, a reputable investor and company builder, as our partner in our mission to revolutionize the treatment of autoimmune and allergic disease.
Q: What were the main challenges you faced in developing the company?
A: Our drug products for Autoimmune and Allergic Disease are unique in how they work. The challenge has been narrowing down our potential pipeline to focus initially on Rheumatoid Arthritis and Allergic disease, in which we have completed Phase 2a clinical trials.
Q: What’s your revenue model? How are you funded?
A: We are funded by high quality healthcare institutional funds such as Morningside Ventures.
Q: What can we expect from Immune Regulation in next 12 months?
A: Advancement of our products 1805 and 1104 into additional phase 2 clinical trials and a build out of our infrastructure in the US and our R&D in the UK.